BridgeMD
New treatment option for HER2-positive Breast Cancer
Official title Evaluation of the Cardioprotective Effect of Nebivolol on Trastuzumab-Induced Cardiotoxicity in Breast Cancer Patients
ClinicalTrials.gov ID: NCT07233499
What this study is testing
What is Nebivolol 5 mg?
Nebivolol 5 mg is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for her2-positive breast cancer.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Breast cancer can be managed using chemotherapy, endocrine therapy and biological therapy. Treatment is determined and specified according to the characteristics of the tumor including overexpression of the human epidermal growth factor receptor (HER2).
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65, women only
You may be able to join if
- Age ≥18 years old.
- Newly diagnosed with early or locally advanced HER2 positive breast cancer.
- Normal baseline LVEF (˃50%)
- Planned to receive HER2-directed therapies as newadjuvant or adjuvant.
You likely can't join if
- Elderly patients( ˃65 years).
- Primary tumors other than breast cancer.
- Pregnancy and breast feeding.
- Currently using cardioprotective drugs e.g.: ACEI, CCB, ARBs and another beta blocker.
- Presence of diagnosed cardiomyopathy currently or in initial evaluation.
- Patients with ischemic heart disease.
See the full eligibility criteria
- Age ≥18 years old.
- Newly diagnosed with early or locally advanced HER2 positive breast cancer.
- Normal baseline LVEF (˃50%)
- Planned to receive HER2-directed therapies as newadjuvant or adjuvant.
- Elderly patients( ˃65 years).
- Primary tumors other than breast cancer.
- Pregnancy and breast feeding.
- Currently using cardioprotective drugs e.g.: ACEI, CCB, ARBs and another beta blocker.
- Presence of diagnosed cardiomyopathy currently or in initial evaluation.
- Patients with ischemic heart disease.
- Contraindication for treatment with beta blockers.
- Patients with hypersensitivity to nebivolol.
- Poorly echogenic patients.
The study team makes the final eligibility decision.
Where it's taking place
- Cairo, Egypt
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Cairo, Egypt. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.